Only 25 percent adapt their diet in a bid to lessen their cancer risk.

Related StoriesScientists discover little molecule that may block growth of BRCA-deficient cancers cellsSausages With Antioxidants From Berries TO AVOID CancerViralytics enters into medical trial collaboration contract with MSDTo help combat this matter a unique selection of dietary supplements has been released, containing evidence-based formulations designed to help reduce the chance of certain diseases. The products, called ProfBiotics, have been produced by medical and dietary experts specifically to support the wellbeing of the bowel, prostate, breasts, liver and pancreas. They contain high degrees of nutrition linked by research to the wellbeing of particular organs in the body – – including lycopene, curcumin, pomegranate, green tea, vitamin D, vitamin E, selenium, vitamin B1 and zinc.Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Tumor Centre, Southern Peninsula and Health Oncology Center in Melbourne, Victoria. The trial will recruit a total of 40 patients. Patients shall be randomised to receive either HA-Irinotecan or irinotecan. The primary endpoint will be tumor stem cell burden during and towards the end of the scholarly study. On the safety side, the trial will measure the incidence of quality 3 and 4 toxicity. Secondary endpoints include Progression-Free Survival . Alchemia will contribute the study drug, HA-Irinotecan, and you will be responsible for the analysis of circulating tumour cells and tumor stem cells.